Related Experiment Videos

[Urinary tract infection and biological markers: C-reactive protein, interleukins and procalcitonin]

D Gendrel1

  • 1Hôpital Saint-Vincent-de-Paul, Paris, France.

Insights

Serum C-reactive protein (CRP) is a useful marker for pediatric urinary tract infection severity. Procalcitonin shows promise for detecting renal scars, though further research on these biomarkers is needed.

Area of Science:

  • Pediatric Nephrology
  • Infectious Diseases
  • Biomarker Research

Background:

  • Urinary tract infections (UTIs) in children can lead to severe complications like renal scarring.
  • Accurate biomarkers are crucial for assessing UTI severity and predicting outcomes.
  • Current markers like C-reactive protein (CRP) have limitations, including false negatives.

Purpose of the Study:

  • To evaluate the prognostic value of serum C-reactive protein (CRP), serum and urinary Interleukin-6 (IL-6), and serum procalcitonin in pediatric UTIs.
  • To compare the effectiveness of these biomarkers in identifying children with renal lesions and scarring.

Main Methods:

  • Analysis of serum CRP, serum IL-6, urinary IL-6, and serum procalcitonin levels in children with UTIs.
  • Correlation of biomarker levels with the presence and severity of renal lesions, assessed by scintigraphy.

Main Results:

  • Serum CRP is a generally reliable marker for UTI severity, despite occasional false negatives.
  • Urinary IL-6 may offer better prognostic value than serum IL-6, as it is elevated in patients with renal lesions, but can be low in some cases.
  • Serum procalcitonin levels correlate with the extent of renal scarring on scintigraphy, with a low false-negative rate (<10%).

Conclusions:

  • Serum CRP remains a valuable, though imperfect, marker for pediatric UTI severity.
  • Urinary IL-6 and particularly serum procalcitonin show potential as prognostic markers for renal involvement in pediatric UTIs.
  • Further studies are warranted to definitively establish the sensitivity and specificity of these biomarkers, especially procalcitonin, for clinical use.

Related Concept Videos